Literature DB >> 25589190

LUX-Lung: determining the best EGFR inhibitor in NSCLC?

Antonio Rossi1, Massimo Di Maio2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25589190     DOI: 10.1016/S1470-2045(14)71196-9

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  6 in total

Review 1.  Small cell lung cancer transformation from EGFR-mutated lung adenocarcinoma: A case report and literatures review.

Authors:  Yangyang Liu
Journal:  Cancer Biol Ther       Date:  2018-03-06       Impact factor: 4.742

2.  Improved overall survival following tyrosine kinase inhibitor treatment in advanced or metastatic non-small-cell lung cancer-the Holy Grail in cancer treatment?

Authors:  Ludger Sellmann; Klaus Fenchel; Wolfram C M Dempke
Journal:  Transl Lung Cancer Res       Date:  2015-06

3.  Histologic Grade Is Predictive of Incidence of Epidermal Growth Factor Receptor Mutations in Metastatic Lung Adenocarcinoma.

Authors:  Michelle Levy; Liisa Lyon; Erika Barbero; John Wong; Marie Suga; Danny Sam; Minggui Pan
Journal:  Med Sci (Basel)       Date:  2017-12-11

4.  Gastric metastasis and transformation of primary lung adenocarcinoma to small cell cancer after acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors: A case report.

Authors:  Jing Liu; Lei Xia; Yuan Peng; Yu Sheng Huang; Zhen Zhou Yang
Journal:  Medicine (Baltimore)       Date:  2021-10-01       Impact factor: 1.889

Review 5.  Small-Cell Lung Cancer Transformation in Patients With Pulmonary Adenocarcinoma: A Case Report and Review of Literature.

Authors:  Shi-Yu Jiang; Jing Zhao; Meng-Zhao Wang; Zhen Huo; Jing Zhang; Wei Zhong; Yan Xu
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.817

6.  Real-World Pattern of Treatment and Clinical Outcomes of EGFR-Mutant Non-Small Cell Lung Cancer in a Single Academic Centre in Quebec.

Authors:  Jason S Agulnik; Goulnar Kasymjanova; Carmela Pepe; Manjusha Hurry; Ryan N Walton; Lama Sakr; Victor Cohen; David Small
Journal:  Curr Oncol       Date:  2021-12-07       Impact factor: 3.677

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.